Compare APPN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPN | XNCR |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 2017 | 2013 |
| Metric | APPN | XNCR |
|---|---|---|
| Price | $38.14 | $24.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $34.00 | $31.42 |
| AVG Volume (30 Days) | 726.6K | ★ 1.0M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $226,743,000.00 | $125,576,000.00 |
| Revenue This Year | $16.88 | $14.05 |
| Revenue Next Year | $10.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 28.29 | 13.65 |
| 52 Week Low | $18.63 | $10.38 |
| 52 Week High | $46.06 | $30.61 |
| Indicator | APPN | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 51.52 |
| Support Level | $33.28 | $23.36 |
| Resistance Level | $39.67 | $30.61 |
| Average True Range (ATR) | 1.78 | 1.03 |
| MACD | -0.40 | -0.09 |
| Stochastic Oscillator | 53.40 | 55.23 |
Appian Corp is an enterprise software company whose platform unifies process orchestration, artificial intelligence, and data for automating complex business operations. Its platform combines low-code application development, process automation and process mining, AI agents, and a data fabric that connects information across an organization's existing systems without replicating it. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based, with the remainder coming from services, and much of that subscription revenue comes from its cloud-based platform. Geographically, the company derives maximum revenue from its Domestic operations and also has a presence internationally.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.